ClinicalTrials.gg

Program

Poliovirus Vaccine, Oral

Also written as “Polio Sabin™”, “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)” and “sIPV+bOPV”.

Its studies are mostly in Streptococcal Infections · Poliomyelitis · Tuberculosis · Hepatitis B · Rotavirus Infections, led by 3 companies.

Furthest: phase 3, since Oct 19, 20076 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline40 open or runningphase 3since Oct 19, 2007Oct 19, 2007none ahead
Beijing Minhai Biotechnology10 open or runningphase 3since Dec 12, 2024Dec 12, 2024none ahead
Merck10 open or runningphase 3since Aug 12, 2005Aug 12, 2005none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2005First study: phase 3 study in Rotavirus InfectionsNew to MerckMerck · NCT00130832 · 735 enrolled
  2. Oct 19, 2007GlaxoSmithKline’s first study: phase 3 study in Streptococcal InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00547248 · 756 enrolled · Philippines, Poland
  3. Mar 18, 2010Phase 2 study in TuberculosisGlaxoSmithKline · NCT01098474 · 301 enrolled · Gambia
  4. Dec 2, 2010Phase 2 study in Streptococcal InfectionsGlaxoSmithKline · NCT01262872 · 1,320 enrolled · Gambia
  5. Oct 20, 2011Phase 3 study in Hepatitis BGlaxoSmithKline · NCT01457560 · 80 enrolled
  6. Dec 12, 2024Beijing Minhai Biotechnology’s first study: phase 3 study in PoliomyelitisNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06752174 · 300 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06752174Poliomyelitis · China3CompletedBeijing Minhai BiotechnologyApr 12, 2024300
NCT01457560Hepatitis B3CompletedGlaxoSmithKlineApr 200180
NCT01262872Streptococcal Infections · Gambia2CompletedGlaxoSmithKlineMar 18, 20131,320
NCT01098474Tuberculosis · Gambia2CompletedGlaxoSmithKlineApr 30, 2011301
NCT00547248Streptococcal Infections · Philippines, Poland3CompletedGlaxoSmithKlineMay 10, 2008756
NCT00130832Rotavirus Infections3CompletedMerckJul 2006735

How it is read

Names in the registry

  • “Polio Sabin™”, 2 entries
  • “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)”, 1 entry
  • “sIPV+bOPV”, 1 entry
  • “Polio Sabin”, 1 entry
  • “bOPV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.